Search

Your search keyword '"García-Goñi, M."' showing total 2 results
Start Over Author "García-Goñi, M." Topic economic evaluation
2 results on '"García-Goñi, M."'

1. Actions to Improve the Secondary Prevention of Fragility Fractures in Women with Postmenopausal Osteoporosis: A Social Return on Investment (SROI) Study

Author

Olmo-Montes FJ, Caeiro-Rey JR, Peris P, Pérez del Río V, Etxebarria-Foronda Í, Cancio-Trujillo JM, Pareja T, Jódar E, Naranjo A, Moro-Álvarez MJ, García-Goñi M, Vergés J, Maratia S, Campos Tapias I, Prades M, and Aceituno S

Subjects
economic evaluation, healthcare investment, prevention measures, healthcare outcomes, fracture liaison services, health-related quality of life, Medicine (General), R5-920, Therapeutics. Pharmacology, RM1-950
Abstract

Francisco Jesús Olmo-Montes,1 José Ramón Caeiro-Rey,2 Pilar Peris,3 Verónica Pérez del Río,4,5 Íñigo Etxebarria-Foronda,6 José Manuel Cancio-Trujillo,7 Teresa Pareja,8 Esteban Jódar,9 Antonio Naranjo,10 María Jesús Moro-Álvarez,11 Manuel García-Goñi,12 Josep Vergés,13 Stefano Maratia,14 Ignasi Campos Tapias,15 Miriam Prades,16 Susana Aceituno16 1Internal Medicine Department, Hospital Universitario Virgen de la Macarena, Sevilla, Spain; 2Traumatology Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain; 3Rheumatology Department, Hospital Clinic de Barcelona, Barcelona, Spain; 4Traumatology Department, Hospital San Juan de la Cruz, Úbeda, Spain; 5Medicine and Dermatology Department, Faculty of Medicine of Universidad de Málaga, Málaga, Spain; 6Traumatology Department, Hospital Alto Deba, Gipuzkoa, Spain; 7Geriatrics Department, Badalona Serveis Assistencials, Badalona, Spain; 8Geriatrics Department, Hospital Universitario de Guadalajara, Guadalajara, Spain; 9Endocrinology Department, Hospital Universitario Quirón de Madrid, Madrid, Spain; 10Rheumatology Department, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Spain; 11Internal Medicine Department, Hospital Central Universitario Cruz Roja “San Jose y Santa Adela”, Madrid, Spain; 12Department of Applied & Structural Economics and History, Faculty of Economics and Business, Universidad Complutense de Madrid, Madrid, Spain; 13Asociación Española con la Osteoporosis y la Artrosis (AECOSAR), Madrid, Spain; 14UCB Pharma S.A., Madrid, Spain; 15Amgen S.A., Barcelona, Spain; 16Outcomes’ 10, S.L.U., Castellón de la Plana, SpainCorrespondence: Antonio Naranjo, Department of Rheumatology, Hospital Universitario de Gran Canaria Doctor Negrín, Barranco de la Ballena s/n, Las Palmas de Gran Canaria, 35011, Spain, Tel +34 928450600, Email anarher@gobiernodecanarias.orgPurpose: This study evaluates the Social Return on Investment (SROI) of implementing measures to prevent fragility fractures in postmenopausal women with osteoporosis (OP) in Spain.Methods: A group of 13 stakeholders identified necessary actions for improving refracture prevention and assessed the investment required from the Spanish National Health System (SNHS), considering direct, indirect, and intangible costs over a one-year period. Unitary costs were sourced from scientific literature and official data, and intangible costs were estimated through surveys on women’s willingness to pay for better health-related quality of life. The SROI ratio was calculated from both a social perspective (including all returns) and the SNHS perspective (including only direct and intangible costs). A sensitivity analysis evaluated the returns in worst- and best-case scenarios over three years.Results: Stakeholders agreed on four main actions: 1) establishing fracture liaison services; 2) harmonizing clinical practice guidelines and provide training for healthcare professionals (HCPs); 3) promoting HCPs’ adherence to fracture registries and 4) raising awareness of OP and fragility fractures. From the social perspective, implementing these actions would cost the SNHS € 4,375,663 but yield a social return of € 96,939,931 in the first year, resulting in a SROI ratio of € 22.15 per euro invested (€ 28.69, 23.14, 24.29, and 10.70 for the four actions, respectively). From the SNHS perspective, the return would be € 36,453,509 (€ 21,523,444 tangible), with a SROI of € 8.33 (€ 4.92 tangible) and for the four actions: € 9.99, 9.39, 8.45, and 3.79, respectively (€ 5.89, 5.54, 4.96 and 2.27 tangible). The investment would be lower than the return for all actions (3.49%, 4.32%, 4.12% and 9.34% of social perspective return, respectively) and scenarios.Conclusion: According to our SROI method, implementing different actions to improve secondary fracture prevention would achieve a considerable social benefit, which, in terms of direct, indirect, and intangible costs, would far outweigh the investment.Keywords: economic evaluation, healthcare investment, prevention measures, healthcare outcomes, fracture liaison services, health-related quality of life

Published
2024

2. A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study)

Author

de Andrés-Nogales F., Cruz E., Calleja M.Á., Delgado O., Gorgas M.Q., Espín J., Mestre-Ferrándiz J., Palau F., Ancochea A., Arce R., Domínguez-Hernández R., Casado M.Á., Gómez Pajuelo P., Gorgas Torner M.Q., López Andrés A., López Rodríguez M., Marín Ballvé A., Martín Herranz M.I., Morell Baladrón A., Sánchez Martínez F.I., Antoñanzas F., Bonanad S., Caballero T., Cabasés J.M., Cruz J., García-Goñi M., Gil R., Pajuelo P.G., Torner M.Q.G., Andrés A.L., Rodríguez M.L., Ballvé A.M., Herranz M.I.M., Baladrón A.M., Mur C., Machado M.P., Martínez F.I.S., Santos A.R., Suárez M., Trillo J.L., the FinMHU-MCDA Group, Institut Català de la Salut, [de Andrés-Nogales F] Pharmacoeconomics & Outcomes Research Iberia (PORIB), 28224 Pozuelo de Alarcón, Spain. [Cruz E] Asociación Española de Medicamentos Biosimilares, Madrid, Spain. [Calleja MA] Servicio de Farmacia, Hospital Universitario Virgen Macarena, Sevilla, Spain. [Delgado O] Servicio de Farmacia, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Gorgas MQ] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Espín J] Escuela Andaluza de Salud Pública, Granada, Spain. Instituto de Investigación Biosanitaria (IBS), Granada, Spain. CIBER de Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus, [de Andrés-Nogales,F, Domínguez-Hernández,R, Casado,MÁ] Pharmacoeconomics & Outcomes Research Iberia (PORIB), Pozuelo de Alarcón, Madrid, Spain. [Cruz,E] Asociación Española de Medicamentos Biosimilares, Madrid, Spain. [Calleja,MÁ] Servicio de Farmacia, Hospital Universitario Virgen Macarena, Sevilla, Spain. [Delgado,O] Servicio de Farmacia, Hospital Universitario Son Espases, Palma de Mallorca, Spain. Servicio de Farmacia, Hospital Universitari Vall D’Hebron, Barcelona, Spain. [Espín,J] Escuela Andaluza de Salud Pública, Granada, Spain. [Espín,J] Instituto de Investigación Biosanitaria (IBS), Granada, Spain. [Espín,J] CIBER de Epidemiología Y Salud Pública (CIBERESP), Madrid, Spain. [Mestre-Ferrándiz,J] Consultor Económico Independiente, Madrid, Spain. [Mestre-Ferrándiz,J] Madrid, Spain. [Palau,F] Servicio de Medicina Genética y CIBERER, Hospital Universitari Sant Joan de Déu, Hospital Clínic y Universitat de Barcelona, Barcelona, Spain. [Ancochea,A] Federación Española de Enfermedades Raras (FEDER), Madrid, Spain. [Arce,R] Asociación Española de Laboratorios de Medicamentos Huérfanos y Ultrahuérfanos (AELMHU), Barcelona, Spain., and This project was carried out with an unrestricted grant from AELMHU (Aso‑ciación Española de Laboratorios de Medicamentos Huérfanos y Ultrahuér‑fanos). AELMHU was not involved in the design of the study and collection, analysis, and interpretation of data and writing the manuscript

Subjects
Orphan Drug Production, Cost-Benefit Analysis, España, Disease, Psychiatry and Psychology::Psychological Phenomena and Processes::Mental Processes::Thinking::Decision Making [Medical Subject Headings], Other subheadings::Other subheadings::/drug therapy [Other subheadings], fenómenos psicológicos::procesos mentales::pensamiento::toma de decisión [PSIQUIATRÍA Y PSICOLOGÍA], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], 0302 clinical medicine, afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::enfermedades raras [ENFERMEDADES], Medicine, Pharmacology (medical), 030212 general & internal medicine, Malalties rares - Tractament, Genetics (clinical), Reimbursement, Multinomial logistic regression, Técnicas de apoyo en la toma de decisiones, 030503 health policy & services, General Medicine, Multiple-criteria decision analysis, Rare diseases, tecnología, industria y agricultura::industria::industria fabril::industria farmacéutica::producción de medicamentos huérfanos [TECNOLOGÍA, INDUSTRIA Y AGRICULTURA], 0305 other medical science, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Decision Support Techniques [Medical Subject Headings], medicine.medical_specialty, Decision Making, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Psychological Phenomena::Mental Processes::Thinking::Decision Making [PSYCHIATRY AND PSYCHOLOGY], Medicaments orfes - Cost-eficàcia, Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Rare Diseases [Medical Subject Headings], Decision Support Techniques, Orphan drug, 03 medical and health sciences, Technology and Food and Beverages::Technology, Industry, and Agriculture::Industry::Drug Industry::Orphan Drug Production [Medical Subject Headings], Quality of life (healthcare), Health Care::Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost-Benefit Analysis [Medical Subject Headings], Rare Diseases, Orphan drugs, Humans, Humanities::Humanities::Philosophy::Life::Quality of Life [Medical Subject Headings], Technology, Industry, and Agriculture::Industry::Manufacturing Industry::Drug Industry::Orphan Drug Production [TECHNOLOGY, INDUSTRY, AND AGRICULTURE], Adverse effect, Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings], business.industry, Enfermedades raras, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Rare Diseases [DISEASES], Research, Multicriteria decision analysis, Medicamento huérfano, Mecanismo de reembolso, Spain, Family medicine, Economic evaluation, Quality of Life, business
Abstract

Background Patient access to orphan medicinal products (OMPs) is limited and varies between countries, reimbursement decisions on OMPs are complex, and there is a need for more transparent processes to know which criteria should be considered to inform these decisions. This study aimed to determine the most relevant criteria for the reimbursement of OMPs in Spain, from a multi-stakeholder perspective, and using multicriteria decision analysis (MCDA). Methods An MCDA was developed in 3 phases and included 28 stakeholders closely related to the field of rare diseases (6 physicians, 5 hospital pharmacists, 7 health economists, 4 patient representatives and 6 members from national and regional health authorities). Initially [phase A], a bibliographic review was conducted to identify the potential reimbursement criteria. Then, a reduced advisory board (8 members) proposed, selected, and defined the final list of criteria that could be relevant for reimbursement. A discrete choice experiment (DCE) [phase B] was developed to determine the relevance and relative importance weight of such criteria according to the stakeholders’ preferences by choosing between pairs of hypothetical financing scenarios. A multinomial logit model was fitted to analyze the DCE responses. Finally [phase C], the advisory board review the results using a deliberative process. Results Thirteen criteria were selected, related to 4 dimensions: patient population, disease, treatment, and economic evaluation. Nine criteria were deemed relevant for decision-making and associated with a higher relative importance: Health-related quality of life (HRQL) (23.53%), treatment efficacy (14.64%), availability of treatment alternatives (13.51%), disease severity (12.62%), avoided costs (11.21%), age of target population (7.75%), safety (seriousness of adverse events) (4.72%), quality of evidence (3.82%) and size of target population (3.12%). The remaining criteria had a Conclusion The reimbursement of OMPs in Spain should be determined by its effect on patient’s HRQL, the extent of its therapeutic benefit from efficacy and the availability of other therapeutic options. Furthermore, the severity of the rare disease should also influence the decision along with the potential of the treatment to avoid associated costs.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results